Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

Chewable erectile dysfunction medications, like chewable Viagra, use the same active ingredients as ED pills, but they aren’t FDA-approved. We review and compare the best options from Hims ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Hims and Roman are telehealth companies that sell prescription and nonprescription products to treat erectile dysfunction (ED), hair loss, and premature ejaculation (PE). Both ED and hair loss can ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions ...

With the FDA shutting down its key revenue stream, Hims faces a tough road ahead--can it justify its valuation?

As stated in my last article, "Amazon's telehealth rollout includes treatment for things like ED and hair loss, which directly competes with Hims & Hers' offerings." And Amazon's pricing strategy ...

Telehealth stock Hims & Hers (HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy. The ad criticized the American ...

Would you like to be notified of the latest news and updates on the stock market?

All three stocks let their investors down last week, but the catalysts are there for all three names to turn things around.

Hims & Hers Health stock has surged 212% since ... announced its plans to expand into hair loss and ED (erectile dysfunction) treatment sectors through its One Medical telehealth service.